Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In this study, the inhibitors of calcium release-activated calcium channel (CRAC), including small molecular compound YM-58483, neutralizing antibody, and shor-harpin RNA, were used to investigate the feasibility in the treatment of rheumatoid arthritis (RA). The efficacy of CRAC inhibitors was demonstrated according to the results of this study. The CRAC inhibitors are expected as a group of new globle immunosuppressants.
|